(Q37100309)

18 August 2017

1 reference

title

Intradermal hepatitis B vaccination (English)

1 reference

18 August 2017

Intradermal Hepatitis B Vaccination (English)

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

5 December 2022

1 reference

M. P. Rivey

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1831579

5 December 2022

J. Peterson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1831579

5 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1831579

5 December 2022

publication date

1 June 1991

1 reference

full work available at URL

18 August 2017

http://journals.sagepub.com/doi/pdf/10.1177/106002809102500612

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

DICP : the annals of pharmacotherapy

5 December 2022

published in

1 reference

18 August 2017

volume

25

1 reference

18 August 2017

issue

6

1 reference

18 August 2017

page(s)

628-634

1 reference

The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500612

Hepatitis B infection in the United States. Recent trends and future strategies for control

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500612

Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500612

Intradermal hepatitis B virus vaccine: immunogenicity and side-effects in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500612

Intradermal hepatitis B immunization with yeast-derived vaccine: serological response by sex and age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500612

Immunogenicity of the intradermal route of hepatitis B vaccination with the use of recombinant hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500612

Intradermal inoculation with Heptavax-B. Immune response and histologic evaluation of injection sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500612

Persistence of anti-HBs after intradermal inoculation of reduced doses of hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500612

Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500612

Low-dose (2 micrograms) hepatitis B vaccination in medical students: comparable immunogenicity for intramuscular and intradermal routes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500612

Intradermal hepatitis B vaccine in thalassaemia and sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500612

Intradermal vaccination against hepatitis B virus infection in an endemic area (Nigeria), two year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500612

Plasma-derived vs recombinant hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500612

Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500612

Appraisal of intradermal immunisation against hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500612

INTRADERMAL VACCINATION AGAINST HEPATITIS B

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500612

ENTRADERMAL HEPATITIS B VACCINE

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809102500612

Acceptance of hepatitis B vaccine by hospital personnel

21 January 2018

5

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis

5 December 2022

8

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

Studies on human epidermal Langerhans cells. I. Allo-activating and antigen-presenting capacity

5 December 2022

9

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men

5 December 2022

10

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

Trials of intradermal hepatitis B vaccines in Gambian children

5 December 2022

15

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

Plasma-derived versus recombinant hepatitis B vaccines

5 December 2022

16

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

Intradermal hepatitis B vaccination for mentally retarded patients

5 December 2022

20

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

Evaluation of a reduced dose of hepatitis B vaccine administered intradermally

5 December 2022

21

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

Intradermal hepatitis B vaccination in an abbreviated schedule

5 December 2022

25

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

Efficacy of hepatitis B immunization with reduced intradermal doses

5 December 2022

26

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

Intradermal, subcutaneous or intramuscular administration of hepatitis B vaccine: side effects and antibody response

5 December 2022

27

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

Comparison of intradermal and intramuscular hepatitis B vaccination in university students

5 December 2022

29

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

Hepatitis B vaccination: how long does protection last?

5 December 2022

33

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

Hepatitis B vaccination: how long does protection last?

5 December 2022

34

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

Drug Intelligence & Clinical Pharmacy

5 December 2022

37

22

985

Howard PA

1988

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine

5 December 2022

38

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

Intradermal hepatitis B vaccine

5 December 2022

39

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

Hypersensitivity to intradermal hepatitis B vaccine

5 December 2022

40

1 reference

https://api.crossref.org/works/10.1177/106002809102500612

5 December 2022

Identifiers

1 reference

18 August 2017

1 reference